Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis

Fig. 2

Methotrexate-induced CXCL12 up-regulation. a CXCL12 plasma levels steadily increase during MTX therapy in all patients. b CXCL12 measurements in MTX responder and MTX nonresponder individuals as defined in Table 2. c CXCL12 levels in patients with and without avascular osteonecrosis. Data collected in weeks 0, 6, and 12 of the MTX treatment are presented in a and from weeks 0 and 12 in b and c. The medians are indicated

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us